Kayque, Cameron, and Brian

ELAPRASE® (idursulfase) is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.

In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.

The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.

Discover ELAPRASE Get Product Support & Assistance
...

How Does
ELAPRASE Work?

ELAPRASE is designed to replace I2S, the enzyme that is deficient or absent in people with Hunter syndrome.

...

Questions About
ELAPRASE

Contact OnePath® for product support, insurance help, co-pay assistance and more.

...

Product Support and Reimbursement

Get key facts and learn how to get assistance with insurance coverage for ELAPRASE.